Mon panier

Human VEGF-B Protein, His Tag

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
VE6-H5225-20ug
$185.00
VE6-H5225-50ug
$400.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    VRF, VEGFL, VEGFB, VEGF-B

  • Source

    Human VEGF-B, His Tag (VE6-H5225) is expressed from human 293 cells (HEK293). It contains AA Pro 22 - Ala 207 (Accession # P49765-1).

    Predicted N-terminus: Pro 22

    Request for sequence
  • Molecular Characterization

    VEGF-B Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 20.3 kDa. The protein migrates as 32-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    VEGF-B SDS-PAGE

    Human VEGF-B, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     VEGF-B ELISA

    Immobilized Human VEGF-B, His Tag (Cat. No. VE6-H5225) at 1 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) with a linear range of 1-32 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     VEGF-B SPR

    Human NRP1, Fc Tag (Cat. No. NR1-H5252) captured on Protein A Chip can bind Human VEGF-B, His Tag (Cat. No. VE6-H5225) with an affinity constant of 23.8 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  VEGF-B SPR

    Human VEGF R1 Protein, Fc Tag (Cat. No. VE1-H5253) captured on Protein A Chip can bind Human VEGF-B, His Tag (Cat. No. VE6-H5225) with an affinity constant of 0.52 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Vascular endothelial growth factor B

  • Catégorie:

  • Nombre de médicaments répertoriés:

    1 Détails

  • Nombre de médicaments cliniques:

    4 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte